Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022

Lilly 's revenue growth in Q1 2022 increased 15%, driven by volume growth of 20%. Excluding revenue from COVID-19 antibodies and Alimta, Q1 2022 revenue grew 10%. Outside of revenue from COVID-19 antibodies, which grew $660 million , revenue was driven by key growth products - consisting of